Stevanato Group SpA
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Stevanato Group SpA.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 13.40 $ to 27.60 $ · Last price: 21.10 $ (As of: September 25, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/25/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Medical Instruments & Supplies
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Stevanato Group SpA STVN | 5.8 | 36.9 | 18.8 | 29.4 | 17.2 | 3.2 | -20.4 |
| Intuitive Surgical Inc ISRG | 143.4 | 50.4 | 32.2 | 66.7 | 30.9 | 20.5 | -7.5 |
| Becton Dickinson and Company BDX | 50.7 | 33.5 | 13.4 | 46.9 | 14.7 | 8.2 | 25.6 |
| Medline Inc. MDLN | 46.7 | 28.9 | 13.8 | 25.1 | 5.4 | 11.5 | – |
| ResMed Inc RMD | 31.7 | 21.6 | 15.0 | 61.6 | 35.3 | 9.8 | -18.2 |
| West Pharmaceutical Services Inc WST | 25.6 | 50.8 | 25.6 | 36.8 | 21.7 | 6.3 | 46.0 |
| Solventum Corp. SOLV | 15.4 | 11.0 | 8.1 | 54.8 | 5.6 | 0.9 | 27.0 |
| Baxter International Inc BAX | 11.8 | – | 25.8 | 34.1 | 6.0 | 5.7 | 7.9 |
| Align Technology Inc ALGN | 10.8 | 25.1 | 10.5 | 70.7 | 16.6 | 0.9 | 17.5 |
| Median of companies shown | 25.6 | 31.2 | 15.0 | 46.9 | 16.6 | 6.3 | 12.7 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year €M
Revenue Operating income Net income
| Fiscal Year | Revenue (€M) | EBIT (€M) | Net Income (€M) | EPS (€) | Operating Cash Flow (€M) | Equity (€M) | Total Assets (€M) |
|---|---|---|---|---|---|---|---|
| 2019 | 537 | 62 | 39 | 0.15 | 43 | 265 | 882 |
| 2020 | 662 | 103 | 79 | 0.30 | 156 | 311 | 968 |
| 2021 | 844 | 162 | 134 | 0.51 | 133 | 842 | 1,419 |
| 2022 | 984 | 192 | 143 | 0.54 | 103 | 996 | 1,660 |
| 2023 | 1,085 | 201 | 146 | 0.55 | 105 | 1,133 | 2,072 |
| 2024 | 1,104 | 161 | 118 | 0.43 | 156 | 1,404 | 2,329 |
| 2025 | 1,139 | 183 | 134 | 0.49 | 275 | 1,486 | 2,543 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales (€M) | Sales YoY (%) | Net Margin (%) | OCF (€M) | FCF (€M) |
|---|---|---|---|---|---|---|---|
| 2024: Q3 | 0.13 | -18.80 | 278 | 2.40 | 10.80 | 112 | -110 |
| 2024: Q4 | 0.19 | 5.60 | 331 | 3.10 | 14.60 | 44 | -45 |
| 2025: Q1 | 0.11 | 22.20 | 257 | 8.70 | 10.30 | 100 | 28 |
| 2025: Q2 | 0.13 | 30.00 | 280 | 7.90 | 10.60 | 45 | -15 |
| 2025: Q3 | 0.16 | 23.10 | 303 | 9.10 | 11.90 | 47 | -1 |
| 2025: Q4 | 0.21 | 9.80 | 343 | 3.80 | 13.70 | 93 | 5 |
| 2026: Q1 | 0.13 | 18.20 | 274 | 6.60 | 10.20 | 76 | 5 |
| 2026: Q2 | 0.16 | 23.10 | 302 | 7.80 | 7.60 | 32 | -34 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 2 of our scanner strategies — each hit links to the scanner.
Growth
Quality & Balance Sheet
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate (€) | EPS Range (€) | Revenue Estimate (€M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.71 | 0.69 – 0.75 | 1,270 | 12.6% | 13 |
| 12/31/2027 | 0.85 | 0.78 – 0.92 | 1,388 | 20.1% | 13 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 5.0%
- More than 10% revenue growth is expected for the coming year -71.8%
- Share count grows by less than 3% a year 1.0%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 5.1%
- Gross margin at 40% or higher and without meaningful erosion 29.0%
- Goodwill from acquisitions does not grow faster than revenue 2.0%
- Net debt below twice EBITDA 1.2 x EBITDA
- Operating cash flow covers the profits of the last three years 138 m
- Return on capital at 15% or higher, or up versus two years ago 9.1%
- Insiders hold at least 10% or are net buyers 1.6%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
8/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 13.4%
- Exp. sales growth 3Y > 5% 10.3%
- EBIT growth 10Y > 5% 19.7%
- Exp. EBIT growth 3Y > 5% 31.2%
- Net debt < 4x EBIT 1.8x
- EBIT positive, 10Y straight 7
- Max. EBIT decline < 50% 19.7%
- Return on equity > 15% 9.6%
- ROCE > 15% 9.1%
- Expected return > 10% 31.7%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
The company
About the Company
Stevanato Group S.p.A. ist im Design, der Produktion und dem Vertrieb von Produkten und Prozessen für Lösungen für die Biopharma- und Gesundheitsindustrie in Europa, dem Nahen Osten, Afrika, Nord- und Südamerika sowie dem asiatisch-pazifischen Raum tätig. Es ist in zwei Segmenten tätig, Biopharmaceutical and Diagnostic Solutions sowie Engineering. Das Unternehmen bietet Arzneimittel-Behältnislösungen an, darunter vorbefüllbare Spritzen, Karpulen, Fläschchen und Ampullen; In-vitro-Diagnostiklösungen; Arzneimittelverabreichungssysteme, darunter Pen-Injektoren, Autoinjektoren und tragbare Injektoren; diagnostische Laborverbrauchsmaterialien; analytische und regulatorische Unterstützungsdienste; Medizinprodukte; pharmazeutische Sichtprüfmaschinen; Montage- und Verpackungsmaschinen; Glasumformungsmaschinen; sowie Kundendienstleistungen wie Linienoptimierung und -umstellung, Schulung, Logistik, Ersatzteile und Wartungsdienste. Es erbringt zudem Auftragsentwicklungs- und -fertigungsdienste für kundeneigene Arzneimittelverabreichungssysteme. Das Unternehmen bedient Pharma-, Biotechnologie-, Diagnostik- und Life-Science-Unternehmen sowie Arzneimittel-, Glasverpackungs- und Fill-and-Finish-Auftragsfertiger. Das Unternehmen wurde 1949 gegründet und hat seinen Hauptsitz in Piombino Dese, Italien. Stevanato Group S.p.A. ist eine Tochtergesellschaft der Stevanato Holding S.R.L.
- Employees
- 6,010
- Headquarters
- Piombino Dese, PD
- Address
- Via Molinella 17, 35017 Piombino Dese, Italy
- Phone
- 39 04 99 31 811
- Website
- stevanatogroup.com
- IPO Date
- 07/16/2021
- ISIN
- IT0005452658
Management
| Name | Title | Birth Year |
|---|---|---|
| Franco Stevanato | CEO & Executive Chairman | 1973 |
| Marco Dal Lago | Chief Financial Officer | 1973 |
| Lisa Miles | Chief Communications & Investor Relations Officer | – |
| Carla Costa | Chief Human Resources Officer | – |
| Mauro Stocchi | Chief Business Officer | 1967 |
| Michele Monico | President of DDS & IVD Business Unit | – |
| Raffaele Pace | President of Engineering Business Unit | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.